Skip to main content
OpenTrials
Completed

NCT Number: NCT02268929

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Albstadt, Germany

Loading trial locations.

About this study

Outcome of both studies (RD001732 and RD001231) will be integrated and additionally reported as PDM-ProValue study program (Integrated Personalized Diabetes Management) due to the high similarity in study characteristics, design and study results.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Existence of a signed Informed Consent form (before any study procedure)
  • Diagnosed Type 2 diabetes mellitus
  • Age =18 years
  • Insulin therapy for =6 months: BOT, SIT, CT or ICT
  • HbA1c =7.5% within the last 6 weeks before study visit 1 (patient's inclusion)
  • Longer-term diabetes care by the trial site (at least for the duration of the 12-month study participation)
  • General practitioner is the primary practitioner in the diabetes care of the patient
  • Insured by the statutory health insurance (GKV) as a statutory or voluntarily insured member or as a family co-insured member
  • Willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written

Exclusion criteria

  • Diabetes treatment by insulin pump therapy (CSII)
  • Experience with the use of special software for systematic processing of SMBG data, e.g. the Accu-Chek® Smart Pix System/Software, the Accu-Chek® 360° Software and/or the Diabetes Software DIABASS
  • Presence of terminal renal failure / dialysis and/or a loss of sight or a tumor illness
  • Chronic use of steroids in adrenal suppressant doses, of other immuno-modulatory drugs or chemotherapy
  • Known alcohol, drug and medication abuse
  • Known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement)
  • Existing pregnancy, breast-feeding or plan to become pregnant during study participation
  • Physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently
  • Dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member

Treatment and study plan

Accu-Chek Smart Pix Software

Device

Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

Accu-Chek Smart Pix readout Device

Device

Smartpix device for data upload out from blood glucose meter devices

Primary outcomes

  1. The mean HbA1c change by Generalized Estimating Equations (GEE) methods

    Time frame: from Baseline to 12 months

Secondary outcomes

  1. Effects of integrated Personalized Diabetes Management (PDM) by means of Generalized Estimating Equations [GEE] methods

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Collaborators

  • Roche Diabetes Care

Registry information

Official study title

Integrated Personalized Diabetes Management (Integrated PDM):Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Integrated PDM in the Care of People With Type 2 Diabetes in General Medical Practices in Germany (GP).

Acronym: PDM-ProValueGP

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Oct 20, 2014
Registry last updated
Nov 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.